Antiphospholipide antibodies subtypes in systemic lupus erythematosus and antiphospholipid syndrome

Objective. То study frequency and clinical significance of different antiphospholipid antibodies (APHLA): anti- cardiolipin (АСА), anti-?2 glycoprotein (AB2), anti-annexin V (AAV) and autoantibodies to oxidized low density lipoproteins (AOLDPL) in pts with systemic lupus erythematosus (SLE) with and without antiphospholipid syndrome (APS). Material and methods. 68 pts (14 male, 54 female, mean age 35,2+11,4 years) followed up in the Institute оГ Rheumatology were included. 45 of them had SLE and 23 - primary APS. 24 from 45 SLE pts had signs of APS. Only instrumentally verified thromboembolic events were recorded. 43 from 68 (63,2%) pts had history of thrombosis. АСА, AB2, AAV and AOLDPL serum level was examined with immuno-enzyme assay. IgG АСА level was in the Institute of Rheumatology of RAMS and in the Institute of Rfeumatology of Warsaw. Lupus anticoagulant was tested with phospholipids-dependent method in platelet depleted plasma. Results. IgG АСА were more frequently revealed in the Institute of Rheumatology of RAMS and were associated with the presence of APS. In the Warsaw laboratory IgG positivity in SLE was revealed in 29%, in SLE+APS - in 33%, in primary APS - in 39%. in half of the pts IgG АСА level was doubtful or low-positive. Thromboembolic events were associated with the presence of IgG AB2 (mean level 0,292 U of OP, median 0,157, minimum - 0,049, maximum 0,994, interquartile dispersion 0,251). Mean level in the absence of thrombosis was 0, 178 U of OP (median 0,112, minimum - 0,440, maximum 0,834, interquartile dispersion 0,100), p=0,003 according to Mann-Whitney test. There was no statistical dependence between IgG АСА, IgG AAV and Ihrom- boembolic events but very high levels of antibodies were present in the group of pts with thromboses. There was a correlation between SLE activity and high AOLDPL level. Mean value of SLEDAI scale in 16 SLE pts with high AOLDPL level was 22,6+4,34 compared with 8,37+3,52 (p=0,000I) in 22 SLE pts not having these antibodies. Conclusion. Presence of IgG AB2 is associated with thromboses independently of their localization. Presence of AOLDPL was associated with disease activity.

anriphospholipid syndrome, antiphospholipid antibodies, aiiti-p2 glycoprotein antibodies, anti-annex- in V antibodies, autoantibodies to oxidized low density lipoproteins

1. <div><p>Wilson W.A., Gharavi А.Е., Koike Т. et al.International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthr. Rheum., 1999,42, 1309-1311</p><p>Asherson R.A, Cervera R. 'Primary', 'secondary' and other variants of the antiphospholipid syndrome. Lupus, 1994, 3, 293-298</p><p>Насонов Е.Л. Антифосфолипидный синдром. М.,Литгера, 2004,440с</p><p>Tsutsumi A, Matsuura Е., Ichikawa К., et al. Antibodies to beta2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthr. Rheum., 1996, 39,14661474</p><p>Balestrieri G., Tincani A., Spatola L. et al. Anti |32-glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus, 1995, 4, 122-130</p><p>Le Tonqueze М., Salozhin K., Dueymes M.et al. Role of beta2- glycoprotein 1 in the antiphospholipid antibody binding to endothelial cells. Lupus, 1995, 4,179-186</p><p>de Groot P.G., Derksem R.H.W.M. Protein С pathway, antiphospholipid antibodies and thrombosis. Lupus, 1994, 3, 229-233</p><p>Roubey R.A. Immunology of the antiphospholipid antibody syndrome. Arthr. Rheum., 1996,39,1444-1454</p><p>Radulescu L., Stancu C., Antohe F. Antibodies against human oxidized low-density lipoprotein (LDL) as markers for human plasma modified lipipoproteins. Mcd.Sci.Monit., 2004, 10(7), 207-214</p><p>Tan E.M., Cohen A.S., Fries J.F et al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr.Rheum., 1982, 25, 1271-1277</p><p>Александрова E.H., Насонов Е.Л., Ковалев В.Ю. Количественный иммуноферментный метод определения антител к кардиолипину в сыворотке крови. Клин, ревматол., 1995, 4 35-39</p><p>Brandt J.T., Triplett D.A., Aving В., Scharrer I. Criteria for the diagnosis of lupus anticoagulant: An update. Thromb. Haemost., 1995, 74, 1185-1190</p><p>Баркаган 3.C., Момот А.П. Основы диагностики нарушений гемостаза. Москва.”Ньюдиамед-АО", 1999,.215с</p><p>Harris E.N., Gharavi А.Е., Boey M.L. et al. Anticardiolipin antibodies: detection by radioimmunoassay and assotiation with thrombosis in systemic lupus erythematosus. Lancet,1983,2,1211-1214</p><p>Harris E.N., Gharavi A.E., Patel S.P., Hughes G.R.V. Anticardiolipin antibody testing. The need for standardization. Arthr. Rheum., 1987,30,835-836</p><p>Harris E.N., Gharavi A.E., Patel S.P., Hughes G.R.V. Evalution of the anticardiolipin antibody test: Report of standartization workshop held in April 1986. Clin.Expe.Immuno!., 1987,68,215222</p><p>Harris E.N., Pierangeli S., Birch D. Anticardiolipin VJel Workshop Report. Fifth International Symposium on Antiphospholipid antibodies. Am.J.Clin.Pathol., 1994,101,616624</p><p>Carreras L.O., Forastiero R.R., Martinuzzo M.E. Which are the best biological markers of the antiphospholipid syndrome? J.Autoimmunity, 2000,15,163-172</p><p>Coulam C.B., McIntyre J.A., Wagenknecht D., Rote N. Interlaboratories inconsistencies in detection of anticardiolipin antibodies. Lancet, 1990,335,865</p><p>Tincani A., Balestrieri G., Allegri F. et al. Overview on Anticardiolipin ELISA Standartisation. J.Autoimmunity, 2000,15,195-197</p><p>Решетняк T.M., Алекберова 3.C., ЕЛ.Насонов и соавт. Антитела к р2-гликопротеину I новый тип антифосфолипид- ных антител. Клин, мед., 1998, 3,36-40</p><p>Reutelingsperger СРМ. Annexins: Key regulators of haemostasis, thrombosis, and apoptosis. Thromb. Haemost., 2001, 86, 413-419</p><p>Lakos G., Kiss E., Regeczy N. et al. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune disease. J.Rheumatol., 2000,27,924-929</p><p>Rand J.H. Antiphospholipid antibody - mediated disruption of the annexine V antithrombotic shield. A thrombogenic mechanism for antiphospholipid syndrome. J.Autoimmunity, 2000, 15, 107-111</p><p>Siaka C., Lambert М., Caron C. et al. Low prewalence of antiannexin V antibodies in antiphospholipid syndrome with fetal loss. RevMed.Interne, 1999,20,762-765</p><p>Haem G., Nicaise-Roland P., Palazzo E. et al. Antioxidized low- dcnsity-Iipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus, 2001, 10,346-351</p><p>Gomez-Zumaquero J.M., Tinahones F.J., De Ramon E. et al. Association of biological markers of activity of systemic lupus erythematosus with levels of anti-oxidized low-density lipoprotein antibodies. Rheumatology (Oxford), 2004, 43 (4), 510-513</p><p>Romero F.L, Amengual O., Atsumi T. et al. Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti beta2-glycoprotein I antibodies but not with antibodies against oxodozed low-density lipoprotein. Br.J.Rheumatol.</p></div><br />